Stifel analyst Benjamin Burnett keeps his buy rating and contends that any weakness in shares of Atara Biotherapeutics on the news that Chris Haqq has resigned as Chief Scientific Officer is an over-reaction. The analyst states that the reason for Haqq's speculated and unconfirmed departure is personal and not indicative of his confidence toward Atara's programs. Burnett notes that in his new reported post at Elicio Therapeutics, Haqq would oversee the development RAS-targeting immunotherapy, potentially related to the treatment of his father who has been diagnosed with brain cancer. The analyst further states that he remains positive on Atara Biotherapeutics stock, citing his view that its "undervalued' technology will be de-risked with a "meaningful" event for its platform next year.